Introduction {#s1}
============

The neointimal healing response after stenting strongly determines the long-term outcome. In the era of bare-metal stents (BMS), the concern was focused on an exaggerated neointimal proliferation, often leading to restenosis, that accounted for 20.0--50.3% of the cases.^[@EHR182C1]^ Drug-eluting stents (DES) have reduced the restenosis rates to 7.9--8.9%,^[@EHR182C1]^ due to their ability to inhibit cellular proliferation. However, since some reports suggested an eventually higher incidence of late and very late stent thrombosis in DES,^[@EHR182C2]--[@EHR182C5]^ the concern shifted to the opposite pole: avoiding an incomplete neointimal coverage of the metallic scaffold that might eventually pose a risk for stent thrombosis.^[@EHR182C6]--[@EHR182C10]^ Intense research is currently aimed to promote optimal neointimal healing.^[@EHR182C11]^

The neointimal healing response can be quantified *in vivo* by invasive imaging techniques. Intravascular ultrasound (IVUS) can quantify neointimal hyperplasia (NIH) and discern whether it is exaggerated, but it cannot assess the completeness of healing, because the thin neointimal layer covering the DES struts is often below IVUS axial resolution (100 µm). Optical coherence tomography (OCT) provides an axial resolution of 10--15 µm, thus enabling accurate evaluation of tissue coverage after stenting. Optical coherence tomography coverage correlates well with histological neointimal healing and endothelialization after stenting in animal models,^[@EHR182C12]--[@EHR182C15]^ thus constituting an *in vivo* surrogate to estimate the completeness of neointimal healing.^[@EHR182C14],[@EHR182C15]^ Optical coherence tomography has become an exploratory tool for the evaluation of healing in studies comparing different types of DES.^[@EHR182C16]--[@EHR182C18]^

The polymers releasing the drug play a role in the modulation of the neointimal response after stenting. In the first-generation DES, some polymers were believed to induce allergic reactions and inflammation, resulting in incomplete neointimal healing and ultimately stent thrombosis.^[@EHR182C10],[@EHR182C19]^ The second generation of polymer coatings is designed to enhance biocompatibility and minimize the inflammatory reaction through different approaches.^[@EHR182C16],[@EHR182C20]^ The BioLinx polymer (Medtronic Inc., Santa Rosa, CA, USA) comprises three different polymers: (i) the hydrophobic C10 acts as a drug reservoir for a slow and sustained release, (ii) the hydrophilic polyvinyl-pyrrolidinone improves biocompatibility, and (iii) C19 contains both hydrophobic and hydrophilic polyvinyl-pyrrolidinone groups playing a role in the control of drug release and in the biocompatibility, respectively. The blend acts as an amphiphilic molecule, with topographic orientation of its hydrophilic components towards the surface in contact with the cells,^[@EHR182C21],[@EHR182C22]^ thus improving the biocompatibility, since hydrophilic polymers do not induce activated monocyte adhesion,^[@EHR182C23]^ which is associated with local inflammation and vascular cell proliferation.^[@EHR182C24]^ The BioLinx polymer also enables a finer and more sustained drug elution. In the porcine model, 85% of the drug content is eluted into tissue during the first 60 days and the remainder is completely eluted by 180 days.^[@EHR182C25]^ Another contemporary biocompatible polymer is the fluoropolymer, poly(vinylidene fluoride-co-hexafluoropropylene). The fluoropolymer surface is hydrophobic, but elicits a biological response known as 'fluoropassivation\' which consists of minimizing the fibrin deposition and thrombogenicity, reducing the inflammatory reaction and enhancing a faster neointimal healing.^[@EHR182C26],[@EHR182C27]^ Preferential affinity of fluorinated surfaces for albumin, with respect to fibrin, and the inhibitory effect of fluorination on platelets adhesion/activation or leucocytes recruitment have been postulated as mechanisms to explain this phenomenon.

The BioLinx polymer is a component of the Resolute stent (Medtronic), together with the Driver BMS (Medtronic) and the antiproliferative agent zotarolimus, at a dose of 160 µg/cm^2^.^[@EHR182C21]^ The stent has proven excellent clinical and angiographic results in selected groups.^[@EHR182C28]--[@EHR182C30]^ The RESOLUTE All Comers trial (NCT00617084) compared for the first time the Resolute zotarolimus-eluting stent (ZES) vs. another DES (XIENCE V, Abbott Vascular, Santa Clara, CA, USA) in an 'all-comers\' patient population, with a non-inferiority design.^[@EHR182C31]^ XIENCE V is an everolimus-eluting stent (EES) at a dose of 100 µg/cm^2^ of stent surface, coated with a fluoropolymer, designed to release 80% of the everolimus in the first 30 days after deployment.^[@EHR182C32]^ ZES proved to be non-inferior to EES for target-lesion failure, a composite of cardiac death, myocardial infarction, and clinically indicated target-lesion revascularization.^[@EHR182C31]^ Nevertheless, the interpretation of the stent thrombosis rates is still a matter of dispute: definite stent thrombosis was significantly higher in ZES than in EES (1.2 vs. 0.3%) at 1 year, but there were no significant differences in definite/probable stent thrombosis.^[@EHR182C31]^ In order to better understand these clinical results, this OCT substudy of the RESOLUTE All Comers trial compares the neointimal coverage of both devices 13 months after implantation.

Methods {#s2}
=======

The design and main results from the RESOLUTE All Comers have been published elsewhere.^[@EHR182C31]^ It was an international, multicentre, prospective, randomized, open-label non-inferiority trial comparing the Resolute ZES, with BioLinx polymer vs. the XIENCE V EES, with fluoropolymer coating. Patient eligibility followed a real-world all-comers design, including patients with symptomatic coronary heart disease with every possible presentation or with silent ischaemia, with one or more coronary artery stenoses \>50% in 2.25--4.00 mm diameter vessels, susceptible to be treated with either of the two devices. There were no limitations regarding the number of lesions or vessels treated, or lesion length. Exclusion criteria comprised known allergy to anti-platelet/anti-thrombotic regimes, or to any of the components of the two stents of the study. Planned surgery in the following 6 months after PCI was also an exclusion criterion. The primary endpoint was target-lesion failure, a composite of cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), and clinically indicated target-lesion revascularization at 1-year follow-up.

Twenty per cent of the patients were randomly selected for an angiographic substudy, thus undergoing quantitative coronary angiography (QCA) at baseline and repeat angiography at 13-month follow-up. Optical coherence tomography was performed in patients in the angiographic substudy from selected sites in which OCT was available. The sample size was calculated for the angiographic substudy,^[@EHR182C31]^ but no formal sample size calculation based on an endpoint hypothesis was performed for the OCT substudy, because no evidence about the expected magnitude of the effect was available when the trial was designed. Based on unpublished data and on the expertise of the investigators with other ongoing OCT trials, a minimum number of 50 patients was considered necessary to provide reliable and non-trivial results.

Several clinical, angiographic, and OCT variables were identified as secondary endpoints in the main RESOLUTE All Comers trial. The principal OCT endpoint was tissue coverage, evaluated as the completeness of coverage (proportion of uncovered struts per stent) and as the mean thickness of coverage. Additional OCT endpoints included apposition and standard areas and volumes.

Optical coherence tomography analysis {#s2a}
-------------------------------------

Optical coherence tomography pullbacks were obtained at 13-month follow-up with M2, M3, or C7 systems (Lightlab Imaging, Westford, MA, USA), depending on the site, using an occlusive or a non-occlusive technique, as appropriate^[@EHR182C33]^ (*Table [1](#EHR182TB1){ref-type="table"}*). Table 1Characteristics of the different optical coherence tomography systems^a^ in the studyM2M3C7TechniqueOcclusiveNon-occlusiveNon-occlusiveDomainTimeTimeFourierCatheterImageWireImageWireDragonflyRotation speed (frames/s)15.620100Pullback speed (mm/s)2320Patients with ZES1920Patients with EES2917Total31837[^1][^2]

Optical coherence tomography pullbacks were analysed offline in a core laboratory (Cardialysis BV, Rotterdam, The Netherlands) by independent analysts blinded to stent-type allocation and clinical and procedural characteristics of the patients, using proprietary software (Lightlab Imaging). Cross-sections at 1 mm intervals within the stented segment and 5 mm proximal and distal to the stent edges were analysed. Lumen and stent areas were drawn in each analysed cross-section, and the derived incomplete stent apposition (ISA) or NIH areas were calculated as appropriate. A metallic strut typically appears as a bright signal-intense structure with dorsal shadowing. Apposition was assessed strut by strut by measuring the distance between the strut marker and the lumen contour. The marker of each strut was placed at the endoluminal leading edge, in the mid-point of its long axis, and the distance was measured following a straight line connecting this marker with the centre of gravity of the vessel^[@EHR182C34]^ (*Figure [1](#EHR182F1){ref-type="fig"}*). Struts with distance to lumen contour larger than the sum of strut + polymer thickness were considered malapposed. This resulted in ISA thresholds of \>97 µm for ZES and \>89 µm for EES. Struts located at the ostium of side branches, with no vessel wall behind, were labelled as non-apposed side-branch (NASB) struts and excluded from the analysis of apposition (*Figure [1](#EHR182F1){ref-type="fig"}*). Figure 1Categories of apposition. Optical coherence tomography cross-sections showing examples of struts in the three different categories of apposition: well-apposed (white arrows), incomplete stent apposition (orange arrows), and; NASB, non-apposed side branch.

Struts were classified as uncovered if any part of the strut was visibly exposed to the lumen, or covered if a layer of tissue was visible over all the reflecting surfaces. In covered struts, the thickness of coverage was measured from the strut marker to the endoluminal edge of the tissue coverage, following a straight line connecting the strut marker with the centre of gravity of the vessel (*Figure [2](#EHR182F2){ref-type="fig"}*). Figure 2Coverage. Optical coherence tomography cross-sections showing examples of covered (white arrows) and non-covered struts (red arrows).

To summarize the spatial distribution of the uncovered struts along the stents, 'spread-out-vessel graphics\' were created by correlating the longitudinal distance from the distal edge of the stent to the strut (abscises) with the angle where the struts were located in the circular cross-section section respect to the centre of gravity of the vessel (ordinates). The resultant graphic represented the stented vessel, as if it had been cut longitudinally along the reference angle 0° and spread out on a flat surface (*Figure [3](#EHR182F3){ref-type="fig"}*). Figure 3Spread-out-vessel graph, illustrative cases. The *X*-axis represents the distance from the distal edge of the stent to the strut; the *Y*-axis represents the angle where the strut is located in the circular cross-section with respect to the centre of gravity of the vessel. The result is a graphic representing the spatial distribution of the non-covered struts (red spots) along the stent, as if it had been cut along the reference angle (0°) and spread out on a flat surface.

Statistical analysis {#s2b}
--------------------

Results are reported as mean ± standard deviation for continuous variables and as count (%) for nominal variables. Continuous variables with normal distribution were compared with Student\'s *t*-test for independent samples or with the Mann--Whitney *U*-test in the case that normal distribution could not be assumed. Nominal variables were compared with Fisher\'s exact test.

In the per strut analysis, apposition was estimated through a categorical variable, comprising three possible excluding categories (well apposed, ISA, or NASB). Tissue coverage was estimated through the proportion of uncovered struts (dichotomous variable) and through the mean thickness of coverage (continuous). Dichotomous or categorical variables were analysed using multilevel logistic regression models with random effects at four different levels: (i) treatment arm, (ii) patient, (iii) lesion, and (iv) stent. Likewise, continuous variables were analysed using multilevel linear regression models with random effects at the same four levels. Overlapping stents and stents separated by a gap of \<5 mm length within the same coronary segment were assigned to the same coronary lesion. Overlap segments were considered separate units of clustering at the stent level for the per strut multilevel analysis.

All statistical analyses were performed according to the intention-to-treat as specified in the protocol, using the SAS v8.2 package (SAS Institute Inc., Cary, NC, USA). All tests were two-sided and a *P*-value of \<0.05 was considered statistically significant.

Results {#s3}
=======

Two thousand two hundred and ninety-two patients were enrolled in the RESOLUTE All Comers trial. Fifty-eight patients (30 ZES and 28 EES) with 107 stents in 72 lesions underwent OCT at 13 months. Nine out of 2718 (0.33%) cross-sections were deemed of insufficient quality for the quantitative analysis. In total, 23 197 struts were analysed. *Tables [2](#EHR182TB2){ref-type="table"}[](#EHR182TB3){ref-type="table"}--[4](#EHR182TB4){ref-type="table"}* show the baseline characteristics of patients, procedures, and lesions, respectively, in both treatment arms. The randomization produced comparable groups, except patients who received EES had significantly higher serum levels of creatinine and lower left ventricular ejection fraction than those who received ZES. No clinical events were observed in the patients in the OCT substudy, except for a non-Q-wave myocardial infarction in the EES group. No patient was excluded from the study on the basis of clinical outcomes. Table 2Baseline patient characteristicsZES (*n*= 30)EES (*n*= 28)*P*-valueAge (years)60.9 (12.5)62.6 (8.9)0.547Males23 (76.7%)23 (82.1%)0.749BMI (kg/m^2^)83.7 (18.4)28.8 (4.8)0.476Cardiovascular risk factors Hypertension18 (60.0%)15 (53.6%)0.791 DM7 (23.3%)7 (25%)1.000  Insulin-requiring0 (0.0%)2 (7.1%)0.229 Hypercholesterolaemia21 (70.0%)20 (71.4%)1.000 Smoking18 (60.0%)16 (57.1%)1.000  Current smoker (\<30 days)11 (36.7%)9 (32.1%)0.787 Family history of CHD7 (35.0%)11 (50.0%)0.366Antecedents Previous MI7 (25.0%)9 (32.1%)0.768 Previous PCI8 (26.7%)4 (14.3%)0.336  With BMS1 (3.3%)3 (10.7%)0.344  With DES5 (16.7%)1 (3.6%)0.195 Previous CABG2 (6.7%)3 (10.7%)0.665Clinical presentation Stable angina16 (53.3%)11 (39.3%)0.306 Unstable angina3 (10.0%)5 (17.9%)0.464 Myocardial infarction9 (30%)10 (35.7%)0.781  STEMI6 (20.0%)7 (25.0%)0.757 Silent ischaemia2 (6.7%)2 (7.1%)1.000Serum creatinine (µmol/L)76.2 (18.1)87.4 (23.6)0.048\*Ejection fraction (%)65 (10)55 (11)0.041\*Angiographic characteristics No. of diseased major vessels  One22 (73.3%)22 (78.6%)0.762  Two7 (23.3%)6 (21.4%)1.000  Three1 (3.3%)0 (0.0%)1.000  LM + 3 vessels0 (0.0%)0 (0.0%)NA Syntax score14.13 (12.19)14.19 (9.10)0.984[^3][^4] Table 3Procedural characteristics (per patient)ZES (*n*= 30)EES (*n*= 28)*P*-valueContrast (ml)264.0 (148.6)265.8 (125.4)0.962Procedure duration (min)59.1 (40.3)56.7 (41.8)0.826No. of vessels treated1.30 (0.54)1.21 (0.42)0.501 LAD15 (50.0%)13 (46.4%)0.799 LCX8 (26.7%)9 (32.1%)0.775 RCA15 (50.0%)11 (39.3%)0.441 LM1 (3.3%)1 (3.6%)1.000No. of lesions treated1.4 (0.7)1.5 (0.6)0.711No. of stents implanted2.0 (1.8)2.4 (1.2)0.381Total stented length (mm)40.1 (42.6)47.9 (29.7)0.428Cross-over0 (0.0%)0 (0.0%)NAOn-label use13 (43.3%)10 (35.7%)0.600Long lesion (\>27 mm)^a^3 (12.0%)3 (13.6%)1.000Small vessel (\<2.5 mm diameter)^a^12 (48.0%)15 (68.2%)0.238Anti-platelet therapy Dual at 6 months28 (93.3%)27 (96.4%)1.000 Dual at 12 months27 (90.0%)26 (92.9%)1.000 Aspirin at 12 months28 (93.3%)27 (96.4%)1.000 Clopidogrel at 12 months29 (96.7%)27 (96.4%)1.000[^5][^6] Table 4Lesions characteristicsZES (*n*= 36)EES (*n*= 36)*P*-valueTarget vessel LM0 (0.0%)1 (2.8%)1.000 LAD14 (38.9%)15 (41.7%)1.000 LCX5 (13.9%)6 (16.7%)1.000 RCA17 (47.2%)14 (38.9%)0.634Pre-procedural TIMI flow 06 (16.7%)6 (16.7%)1.000 I1 (2.8%)2 (5.6%)1.000 II3 (8.3%)2 (5.6%)1.000 III26 (72.2%)26 (72.2%)1.000Post-procedural TIMI flow II1 (2.8%)0 (0.0%)1.000 III35 (97.2%)36 (100.0%)1.000TO6 (16.7%)6 (16.7%)1.000Ostial lesion1 (2.8%)1 (2.8%)1.000Bifurcation8 (22.2%)12 (33.3%)0.430Moderate or severe calcification8 (22.2%)5 (13.9%)0.541Angiographic edge dissections1 (2.8%)0 (0.0%)1.000Complications0 (0.0%)0 (0.0%)NAQCA characteristics Lesion length (mm)16.6 (9.9)13.8 (10.0)0.297 Pre-stenting  RVD (mm)2.84 (0.56)2.59 (0.54)0.089  MLD (mm)0.88 (0.58)0.78 (0.51)0.438  % diam stenosis69 (19)70 (19)0.942 Post-stenting  In-stent  RVD (mm)2.91 (0.49)2.82 (0.45)0.401  MLD (mm)2.44 (0.51)2.40 (0.48)0.717  % diam stenosis16 (8)15 (7)0.476  In-segment  RVD (mm)2.83 (0.47)2.66 (0.46)0.116  MLD (mm)2.15 (0.44)2.01 (0.39)0.161  % diam stenosis24 (9)24 (9)0.923[^7][^8]

*Tables [5](#EHR182TB5){ref-type="table"}* and *[6](#EHR182TB6){ref-type="table"}* show mean in-stent areas and volumes in non-overlapping and overlapping segments, respectively, without significant differences between both stent types. *Table [7](#EHR182TB7){ref-type="table"}* shows the comparative results of the variables estimating apposition and tissue coverage. There were no significant differences in the proportion of non-covered struts or in the mean thickness of coverage between the treatment groups in multilevel analysis. Introducing the variables with imbalanced distribution (serum creatinine and ejection fraction) in the regression model as covariates did not translate into any significant variation in the differences in coverage. Table 5Areas and volumetric analysis per stent (excluding overlapping segments) at 13-month follow-up58 patients, 72 lesions, 107 stentsZES: 30 patients, 36 lesions, 50 stentsEES: 28 patients, 36 lesions, 57 stents*P*-valueStent length (mm)18.7 (9.3)18.6 (8.6)0.959MLA (mm²)5.45 (2.39)5.35 (2.45)0.845Mean lumen area (mm²)6.89 (2.52)6.68 (2.75)0.681Lumen volume (mm^3^)130.1 (80.4)123.2 (73.0)0.641Min stent area (mm²)6.37 (2.41)6.47 (2.42)0.831Mean stent area (mm²)7.70 (2.38)7.64 (2.59)0.902Stent volume (mm^3^)145.2 (85.1)140.8 (77.2)0.777% frames with ISA5.10 (9.84)3.18 (7.00)0.255Max ISA area (mm²)0.39 (0.76)0.49 (1.56)0.666ISA volume (mm^3^)0.79 (1.80)1.08 (3.90)0.615 ISA volume (% of stent volume)0.58 (1.39)0.66 (2.27)0.835Max NIH area (mm²)1.73 (0.82)1.88 (0.87)0.367NIH volume (mm^3^)15.9 (11.6)18.7 (14.4)0.274 NIH volume obstruction (%)12.5 (7.9)15.0 (10.7)0.157[^9] Table 6Areas and volumetric analysis of overlapping segments at 13-month follow-up19 patients, 21 lesions, 28 overlapsZES: 8 patients, 9 lesions, 11 overlapsEES: 11 patients, 12 lesions, 17 overlaps*P*-valueOverlap length (mm)2.4 (2.4)2.1 (2.7)0.771MLA (mm²)5.37 (2.09)6.67 (2.89)0.208Mean lumen Area (mm²)5.61 (2.14)6.93 (2.97)0.213Lumen volume (mm^3^)14.1 (16.2)16.1 (22.8)0.805Min stent area (mm²)6.15 (1.70)7.89 (3.02)0.095Mean stent area (mm²)6.50 (1.68)8.20 (3.00)0.100Stent volume (mm^3^)15.7 (17.3)18.5 (26.2)0.760% frames with ISA3.03 (10.05)2.94 (12.13)0.984Max ISA area (mm²)0.02 (0.08)0.02 (0.07)0.821ISA volume (mm^3^)0.01 (0.04)0.01 (0.04)0.892 ISA volume (% of stent volume)0.10 (0.34)0.24 (0.99)0.601Max NIH area (mm²)1.16 (0.56)1.50 (0.94)0.297NIH volume (mm^3^)1.7 (1.5)2.5 (3.6)0.433 NIH volume obstruction (%)16.0 (12.3)17.0 (11.8)0.835[^10] Table 7Analysis of apposition and coverage per strut at 13-month follow-upAll struts: 58 patients, 72 lesions, 107 stents, 23 197 strutsZES: 30 patients, 36 lesions, 50 stents, 11 930 strutsEES: 28 patients, 36 lesions, 57 stents, 11 267 struts Estimate95% CI*P*-valueLowUpApposition Apposition category  Well-apposed11 624 (97.4%)10 989 (97.5%)OR0.960.521.760.898  ISA216 (1.8%)161 (1.4%)OR1.270.562.910.569  NASB90 (0.8%)117 (1.0%)OR0.720.411.290.271Coverage Thickness of coverage (µm)116 (99)142 (113)Difference−11.4−42.419.650.466 Coverage category  Covered11 043 (92.6%)10 613 (94.2%)OR0.770.431.380.378  Uncovered887 (7.4%)654 (5.8%)OR1.300.722.33Overlapping segments: 19 patients, 21 lesions, 28 overlaps, 1251 struts8 patients, 9 lesions, 11 overlaps, 629 struts11 patients, 12 lesions, 17 overlaps, 622 strutsApposition Apposition category  Well-apposed626 (99.5%)618 (99.4%)OR1.350.1413.500.798  ISA3 (0.5%)1 (0.2%)OR2.980.1947.830.441  NASB0 (0.0%)3 (0.5%)OR---------NACoverage Thickness of coverage (µm)129 (98)171 (125)Difference−47.97−159.3763.440.376 Coverage category  Covered588 (93.5%)600 (96.5%)OR0.530.241.160.111  Uncovered41 (6.5%)22 (3.5%)OR1.890.864.17[^11]

*Figure [4](#EHR182F4){ref-type="fig"}* shows the spread-out-vessel graphics of the 109 stents and corresponding overlaps. Figure 4Spread-out-vessel graphics showing non-covered struts of the 109 stents and corresponding overlaps analysed at 13 months. The graphic summarizes the spatial distribution of non-coverage and its clustering at the four considered levels (allocation to treatment, patient, lesion, and stent).

Discussion {#s4}
==========

The main finding of this study is that OCT did not detect any significant difference between ZES and EES in tissue coverage at 13 months. Both DES have durable polymers, but with different properties. The BioLinx polymer on ZES is an amphiphilic blend of three different polymers, with a hydrophilic surface in contact with the blood or the vessel wall. Conversely, the poly(vinylidene fluoride-co-hexafluoropropylene) on EES offers a hydrophobic fluorinated surface that might induce fluoropassivation. Hydrophilicity (ZES) and fluoropassivation (EES) improve both the biocompatibility of the corresponding intracoronary device, as discussed previously. No significant differences were found in the mean thickness of coverage, although it tended to be thinner in ZES. Likewise, there were no significant differences regarding the proportion of covered struts, a possible surrogate for the completeness of neointimal coverage. In view of these results, a hydrophilic polymer coating does not seem to translate into any clear advantage in terms of neointimal coverage with respect to a hydrophobic fluoropolymer coating. Beyond the hydrophilicity of the polymer surface, other factors such as the different antiproliferative drugs (with different inhibitory potency and dose), the kinetics of release (more sustained release in ZES, prolonged up to 180 days), mechanical characteristics of the stent platform, and the polymer itself play certainly a role in determining the neointimal coverage after stenting. Interestingly, the proportion of uncovered struts in ZES in our study is higher than in previous OCT studies on another ZES with a phosphorylcholine polymer and different kinetics of release.^[@EHR182C18],[@EHR182C35]^ This could be the consequence of the sustained drug elution, although the absolute proportions in these studies cannot be directly compared due to small methodological differences in the assessment.

Since no significant differences in ISA were found between the treatment groups, an eventual confounding effect of ISA on the coverage can be ruled out.

Because the number of patients in the OCT substudy was modest compared with the large numbers in the main trial, and a sizeable number of control variables were tested, some differences appeared by chance between treatment groups in spite of randomization. In order to control potential confusion, an additional sensitivity analysis was performed, introducing the variables with imbalanced distribution as covariates in the multilevel regression models, but the results did not change with respect to the pre-specified analysis.

The results about OCT coverage seem consistent with the clinical findings of the RESOLUTE All Comers trial,^[@EHR182C31]^ in which ZES proved to be non-inferior to EES for target-lesion failure. Furthermore, on the basis of this OCT substudy, differences in coverage cannot be advocated to explain the ambiguous clinical results regarding stent thrombosis. The correlation between OCT substudies and the clinical outcome of large prospective trials can contribute to understand the predictive value of OCT. In the LEADERS trial, the OCT substudy detected an advantage in coverage in one of the stents at 9 months,^[@EHR182C16]^ but no differences in thrombosis rates have been reported hitherto.^[@EHR182C20]^ Likewise, HORIZONS-AMI found worse coverage in DES than in BMS after primary PCI,^[@EHR182C36]^ but no significant difference in thrombosis.^[@EHR182C37]^ In RESOLUTE All Comers, there was a non-significant trend to lower stent thrombosis in the EES group, although most of the events occurred in the first 30 days when neointimal healing is still unlikely to play a role.^[@EHR182C31]^ The results of this OCT substudy could be interpreted as reassuring that factors other than differences in coverage are the key for these clinical results, but the potential of OCT coverage to predict future thrombotic events must be still properly understood.

The 'spread-out-vessel\' summary in *Figure [4](#EHR182F4){ref-type="fig"}* may be the best possible graphic representation for the clustering and spatial distribution of non-coverage. It clearly shows, without the need of complex statistics, that the type of stent is not the only factor determining coverage: concentration of uncovered struts in some patients or in some stents within a patient or in some regions within a stent points out clearly the relevance of individual, mechanical, and loco-regional factors, respectively. Among them, diabetes,^[@EHR182C38]^ levels of circulating endothelial progenitor cells,^[@EHR182C39]^ or regional shear stress^[@EHR182C40],[@EHR182C41]^ are known to play a role in neointimal healing after stenting.

Limitations {#s4a}
-----------

The unequal distribution of some control variables in the randomization has been previously addressed.

Some caution should be advised about using OCT tissue coverage as a surrogate of neointimal healing. Although biologically plausible and intuitively accepted by the scientific community, this approach cannot be fully supported by current evidence. Optical coherence tomography tissue coverage correlates with histological neointimal healing and endothelialization after stenting in animal models,^[@EHR182C12]--[@EHR182C14]^ but its sensitivity and specificity in human atherosclerotic vessels are still unknown. Optical coherence tomography is not able to detect thin layers of the endothelium, below its 10--20 µm axial resolution, and cannot discern between neointima and other material, such as fibrin or thrombus. The analysis of optical density might be useful in the future to discern between neointima and fibrin.^[@EHR182C15]^

Per strut quantitative analysis was performed at 1 mm longitudinal intervals. Although this methodology has been experimentally validated for the assessment of coverage^[@EHR182C14]^ and showed excellent reproducibility,^[@EHR182C34]^ it might have different sensitivity to detect uncovered struts than shorter longitudinal intervals. The results from studies using different longitudinal segmentation might not be directly comparable.

Finally, the OCT substudy of RESOLUTE All Comers did not follow a non-inferiority design, as was done in the main trial. Therefore, the conclusion cannot be the absence of significant differences between the compared stents, in spite of not having found them. The possibility of an underpowered design cannot be strictly ruled out, although the lack of any clear trend between the groups makes it very unlikely.

Conclusion {#s5}
==========

No significant differences in tissue coverage, malapposition, or lumen/stent areas and volumes were detected by OCT between the hydrophilic polymer-coated ZES and the fluoropolymer-coated EES at 13-month follow-up.
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[^1]: ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent.

[^2]: ^a^All systems and catheters from Lightlab Imaging.

[^3]: Data presented as no. of events (%) or mean (SD), as appropriate. BMI, body mass index; BMS, bare-metal stent; CABG, coronary artery bypass graft; CHD, coronary heart disease; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; LM, left main stem; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; ZES, zotarolimus-eluting stent.

[^4]: \**P*≤ 0.05.

[^5]: Data presented as no. of events (%) or mean (SD), as appropriate. EES, everolimus-eluting stent; LAD, left anterior descending; LCX, left circumflex; LM, left main stem; RCA, right coronary artery; ZES, zotarolimus-eluting stent.

[^6]: ^a^Derived from QCA data.

[^7]: Data presented as no. of events (%) or mean (SD), as appropriate. EES, everolimus-eluting stent; LAD, left anterior descending; LCX, left circumflex; LM, left main stem; MLD, minimal lumen diameter; QCA, quantitative coronary angiography; RCA, right coronary artery; RVD, reference vessel diameter; TO, total occlusion; ZES, zotarolimus-eluting stent. Lesion length and RVD were not available for 17 lesions due to initial TIMI flow 0/I; for one lesion in the ZES group, the pre-stenting lesion length, RVD, MLD, and % diameter stenosis could not be determined due to overlapping vessels.

[^8]: \**P*≤ 0.05.

[^9]: Data presented as mean (SD). EES, everolimus-eluting stent; ISA, incomplete stent apposition; MLA, minimal lumen area; NIH, neointimal hyperplasia; ZES, zotarolimus-eluting stent.

[^10]: Data presented as mean (SD). EES, everolimus-eluting stent; ISA, incomplete stent apposition; MLA, minimal lumen area; NIH, neointimal hyperplasia; ZES, zotarolimus-eluting stent.

[^11]: EES, everolimus-eluting stent; ISA, incomplete stent apposition; NASB, non-apposed side branch; ZES, zotarolimus-eluting stent.
